Morgan Stanley: China Healthcare Sector Maintains 'Attractive' Rating, Innovative Drug Market Could Reach 2.5x Current Size by 2030
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Morgan Stanley published a research note on September 21, citing China's 15th Five-Year Plan for the pharmaceutical industry. The plan targets a compound annual growth rate (CAGR) of over 20% for China's innovative drug sector by 2030, which would expand the industry to about 2.5 times its current size. The plan also explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing products with global partners, and strengthens intellectual property protection and regulatory standard coordination, which Morgan Stanley says helps alleviate geopolitical concerns. The bank noted the plan prioritizes AI-enabled applications such as target discovery and molecular design/optimization. In medical devices and diagnostics, the plan supports high-end equipment and precision diagnostics/therapeutics, aiming to launch 200 or more innovative medical devices by 2030. Morgan Stanley maintains an attractive industry view on China's healthcare sector.
Source report
September 21 — Morgan Stanley has released a research report stating that the "15th Five-Year Plan for the Pharmaceutical Industry Development" sets a target for China's innovative drug sector to achieve a compound annual growth rate (CAGR) of over 20% by 2030, which would expand the industry to approximately 2.5 times its current size.
The plan also explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing products with global partners, while strengthening intellectual property protection and regulatory standard alignment. These measures are expected to help alleviate geopolitical concerns.
Morgan Stanley further noted that the plan prioritizes the development of AI-enabled applications, including target discovery and molecular design/optimization.
In the medical devices and diagnostics segment, the plan supports high-end medical equipment and precision diagnostics/therapeutics, with a target of launching 200 or more innovative medical devices by 2030.
The firm maintains an attractive view on China's healthcare sector.
Source
格隆汇Neutral / independent
Part of this Story
China Sets 2030 Targets for 25% Global First-in-Class Drug Share and 20% Annual Growth